Age Related Macular Degeneration News and Research

RSS

Majority of adults need to double consumption of fruits and vegetables for crucial nutrition, health benefits

New research published in the September issue of the British Journal of Nutrition and featured in the just released Global Phytonutrient Report highlights a significant shortfall in fruit and vegetable consumption in people's diets around the world.

12 Aug 2014

European Commission approves EYLEA Injection for treatment of visual impairment due to DME

Regeneron Pharmaceuticals, Inc. today announced that EYLEA® (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Diabetic Macular Edema.

11 Aug 2014

Oraya awarded NIH grant to study how gold nanoparticles can enhance Wet AMD treatment

Oraya Therapeutics, Inc. announced today that they have been awarded a $215,000 Small Business Technology Transfer Grant from the National Institutes of Health to investigate how Oraya Therapy, a low voltage stereotactic radiotherapy, and gold nanoparticles can further enhance the treatment of wet age-related macular degeneration (Wet AMD).

6 Aug 2014

Researchers create most detailed molecular map for region associated with blinding diseases

Understanding eye diseases is tricky enough. Knowing what causes them at the molecular level is even more confounding.

3 Aug 2014

Regeneron announces FDA approval of EYLEA Injection for DME treatment

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME).

31 Jul 2014

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME).

29 Jul 2014

Oraya Therapy now being offered at NHS hospital in the UK and at four prestigious university hospitals in Germany

Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.

22 Jul 2014

Parents severely underestimate time children spend on digital devices

According to the American Optometric Association (AOA), parents severely underestimate the time their children spend on digital devices. An AOA survey reports that 83 percent of children between the ages of 10 and 17 estimate they use an electronic device for three or more hours each day.

22 Jul 2014

Early stage AMD can occur much earlier than previously thought

It is widely accepted that age-related macular degeneration (AMD) is the most common cause of visual impairment and blindness in industrialized countries.

22 Jul 2014

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Regeneron Pharmaceuticals, Inc. today announced that in the Phase 3 VIVID-DME trial of EYLEA® (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100 (2 years), compared to laser photocoagulation.

18 Jul 2014

Integrated therapies can reduce depression by half among people with low vision due to AMD

The first clinical trial to examine integrated low vision and mental health treatment has shown that the approach can reduce the incidence of depression by half among people with low vision due to age-related macular degeneration (AMD).

9 Jul 2014

New approach can reduce depression in patients with AMD-related low vision

Depression is a common risk for people who have lost their vision from age-related macular degeneration (AMD), but a new study shows that a type of rehabilitation therapy can cut this risk in half. The study was funded by the National Eye Institute (NEI), part of the National Institutes of Health.

9 Jul 2014

Metabolic pathway genes linked to AMD and choroidal vasculopathy

The cholesteryl ester transfer protein gene appears to increase susceptibility to neovascular age-related macular degeneration and polypoidal choroidal vasculopathy, research shows.

1 Jul 2014

Reticular drusen linked to AMD progression

Four percent of individuals aged 49 years and above will develop reticular drusen over 15 years of follow-up, Australian study findings suggest, with the incidence higher in those with age-related macular degeneration risk factors.

1 Jul 2014

Study links nearsightedness to higher education and years spent in school

German researchers have found strong evidence that attaining a higher level of education and spending more years in school are two factors associated with a greater prevalence and severity of nearsightedness, or myopia.

28 Jun 2014

Nicox launches expanded access to Sequenom Laboratories' RetnaGene portfolio

Nicox S.A., the international ophthalmic company, and Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that Nicox's subsidiary, Nicox Inc. is launching expanded access to Sequenom Laboratories' RetnaGene™ portfolio of laboratory-developed genetic tests in the United States (U.S.).

19 Jun 2014

Simulator for evaluating effects of visual impairment on person's driving performance

The University of California, San Diego School of Medicine is the first ophthalmology department in the nation to feature a fully dedicated high-fidelity, highly realistic driving simulator for evaluating the effects of visual impairment on a person's driving performance.

16 Jun 2014

Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that Bayer HealthCare has submitted an application to the European Medicines Agency (EMA) seeking marketing authorization in the European Union (EU) for EYLEA (aflibercept) Injection for the treatment of macular edema following branch retinal vein occlusion (BRVO).

11 Jun 2014

Ocugen's OCU100 gets FDA orphan drug designation for treatment of retinitis pigmentosa

Ocugen, Inc. and the University of Colorado today announced exclusive license agreements that allow for Ocugen to continue developing two drug candidates for the treatment for ophthalmology indications, and that one of the assets, OCU100, recombinant lens epithelium derived growth factor 1-326 (LEDGF1-326), received orphan-drug status from the U.S. Food and Drug Administration for treatment of retinitis pigmentosa (RP), a rare eye disease.

6 Jun 2014

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that Ruben Mesa, MD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 14, 2014 at the 19th Congress of European Hematology Association (EHA) which is being held in Milan, Italy, from June 12-15, 2014.

5 Jun 2014

Age Related Macular Degeneration News and Research

Majority of adults need to double consumption of fruits and vegetables for crucial nutrition, health benefits

European Commission approves EYLEA Injection for treatment of visual impairment due to DME

Oraya awarded NIH grant to study how gold nanoparticles can enhance Wet AMD treatment

Researchers create most detailed molecular map for region associated with blinding diseases

Regeneron announces FDA approval of EYLEA Injection for DME treatment

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

Oraya Therapy now being offered at NHS hospital in the UK and at four prestigious university hospitals in Germany

Parents severely underestimate time children spend on digital devices

Early stage AMD can occur much earlier than previously thought

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Integrated therapies can reduce depression by half among people with low vision due to AMD

New approach can reduce depression in patients with AMD-related low vision

Metabolic pathway genes linked to AMD and choroidal vasculopathy

Reticular drusen linked to AMD progression

Study links nearsightedness to higher education and years spent in school

Nicox launches expanded access to Sequenom Laboratories' RetnaGene portfolio

Simulator for evaluating effects of visual impairment on person's driving performance

Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

Ocugen's OCU100 gets FDA orphan drug designation for treatment of retinitis pigmentosa

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News